Clinical Benefit Assessment of Vismodegib Therapy in Patients With Advanced Basal Cell Carcinoma

PURPOSE. Vismodegib was approved for the treatment of advanced basal cell carcinoma (aBCC) based on the pivotal ERIVANCE BCC study. The primary endpoint (objective response rate [ORR]) was assessed 9 months after the last patient was enrolled. To confirm the clinical benefit of vismodegib, an additi...

Disgrifiad llawn

Wedi'i Gadw mewn:
Manylion Llyfryddiaeth
Prif Awduron: Dreno, Brigitte, Basset-Seguin, Nicole, Caro, Ivor, Yue, Huibin, Schadendorf, Dirk
Fformat: Artigo
Iaith:Inglês
Cyhoeddwyd: AlphaMed Press 2014
Pynciau:
Academia-Pharma Intersect
Mynediad Ar-lein:https://ncbi.nlm.nih.gov/pmc/articles/PMC4122481/
https://ncbi.nlm.nih.gov/pubmed/25001266
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1634/theoncologist.2014-0003
Tagiau: Ychwanegu Tag
Dim Tagiau, Byddwch y cyntaf i dagio'r cofnod hwn!

Eitemau Tebyg